Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018
A case control study:The role of leukotriene receptor antagonist in cardiovascular risk Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Severe pulmonary hypertension in chronic lung disease. Long term effects on gas exchange of endothelin receptor antagonists or PDE5 inhibitors Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Looking to the future: a new decade of pulmonary arterial hypertension therapy Source: Eur Respir Rev 2011; 20: 262-269 Year: 2011
Transcriptome profiling reveals a potential role for antagonism of the calcium-sensing receptor in the prophylaxis of idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018
Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004
Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007
The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension Source: Eur Respir J 2016; 48: 470-483 Year: 2016